Trial Profile
A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 8055 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 14 Jun 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 14 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Actual initiation date changed from Sep 2009 to Aug 2009 as reported by ClinicalTrials.gov.